Literature DB >> 35284318

A comprehensive analysis of the diagnostic and prognostic value associated with the SLC7A family members in breast cancer.

Liping Yan1,2, Jianxin He3, Xiwen Liao1, Tianyi Liang1, Jia Zhu4, Wensong Wei5, Yongfei He1, Xin Zhou1, Tao Peng1,2.   

Abstract

Background: The solute carrier (SLC) 7 family genes play central roles in cancer cell metabolism as glucose and glutamate transporters. However, their expression and prognostic value in breast cancer (BC) remains to be elucidated.
Methods: Clinical data from BC patients were downloaded from The Cancer Genome Atlas (TCGA) and the Kaplan-Meier (KM) plotter database. The mechanisms underlying the association between SLC7A expression and overall survival (OS) were explored using Cox regression and log-rank tests. ESTIMATE gives a measure of the immune-cell infiltrates. Single-sample (ss) Gene Set Enrichment Analysis (GSEA) was conducted to quantify immune cell infiltration.
Results: High SLC7A5 expression was associated with a poorer survival time in BC patients according to the TCGA and KM plotter data. SLC7A4 was associated with good progression-free interval (PFI) and disease-specific survival (DSS) according to the TCGA data. Furthermore, SLC7A4 was correlated with good prognosis of OS, distant metastasis-free survival (DMFS), relapse-free survival (RFS), and post-progression survival (PPS) according to the KM plotter data. SLC7A3 expression was positively associated with OS, but was not strongly associated with PFI nor DSS in the TCGA data. However, SLC7A3 was positively correlated with DMFS and RFS in the KM database analysis. SLC7A had excellent diagnostic value in BC patients and was strongly correlated with tumor infiltration. T helper 2 (Th2) cells, CD56 bright natural killer (NK) cells, and NK cells were the most strongly correlated with the SLC7A family genes, suggesting that these genes play a crucial role in BC partly by modulating immune infiltration. Conclusions: SLC7A4 and SLC7A5 expression levels may be sensitive biomarkers for predicting BC outcomes. SLC7A3 may be a potential diagnostic and prognostic biomarker in BC, but further studies are warranted to verify these results. 2022 Gland Surgery. All rights reserved.

Entities:  

Keywords:  Breast cancer (BC); biomarker; immune infiltration; prognosis; solute carrier family 7

Year:  2022        PMID: 35284318      PMCID: PMC8899434          DOI: 10.21037/gs-21-909

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  64 in total

1.  The Role of Large Neutral Amino Acid Transporter (LAT1) in Cancer.

Authors:  Xinjie Lu
Journal:  Curr Cancer Drug Targets       Date:  2019       Impact factor: 3.428

2.  Stromal gene expression predicts clinical outcome in breast cancer.

Authors:  Greg Finak; Nicholas Bertos; Francois Pepin; Svetlana Sadekova; Margarita Souleimanova; Hong Zhao; Haiying Chen; Gulbeyaz Omeroglu; Sarkis Meterissian; Atilla Omeroglu; Michael Hallett; Morag Park
Journal:  Nat Med       Date:  2008-04-27       Impact factor: 53.440

Review 3.  The SLC3 and SLC7 families of amino acid transporters.

Authors:  Dimitrios Fotiadis; Yoshikatsu Kanai; Manuel Palacín
Journal:  Mol Aspects Med       Date:  2013 Apr-Jun

4.  An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics.

Authors:  Jianfang Liu; Tara Lichtenberg; Katherine A Hoadley; Laila M Poisson; Alexander J Lazar; Andrew D Cherniack; Albert J Kovatich; Christopher C Benz; Douglas A Levine; Adrian V Lee; Larsson Omberg; Denise M Wolf; Craig D Shriver; Vesteinn Thorsson; Hai Hu
Journal:  Cell       Date:  2018-04-05       Impact factor: 41.582

5.  LAT1 (SLC7A5) Overexpression in Negative Her2 Group of Breast Cancer: A Potential Therapy Target.

Authors:  Khaldon Bodoor; Rowida Almomani; Mohammad Alqudah; Yazan Haddad; Walaa Samouri
Journal:  Asian Pac J Cancer Prev       Date:  2020-05-01

Review 6.  The Harmonious Interplay of Amino Acid and Monocarboxylate Transporters Induces the Robustness of Cancer Cells.

Authors:  Go J Yoshida
Journal:  Metabolites       Date:  2021-01-02

7.  SLC7A5 serves as a prognostic factor of breast cancer and promotes cell proliferation through activating AKT/mTORC1 signaling pathway.

Authors:  Yuan Li; Wei Wang; Xue Wu; Sunkai Ling; Yu Ma; Peilin Huang
Journal:  Ann Transl Med       Date:  2021-05

8.  The genetic landscape of the human solute carrier (SLC) transporter superfamily.

Authors:  Lena Schaller; Volker M Lauschke
Journal:  Hum Genet       Date:  2019-11-02       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.